KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)

被引：0
|
作者：
Lai, W. C. V. [1 ]
Ahn, M-J. [2 ]
Shentzer, T. [3 ]
Kowalski, D. [4 ]
Cho, B. C. [5 ]
Schmid, S. [6 ]
Jove, M. [7 ]
Huang, M. [8 ]
Zhao, B. [8 ]
El-Osta, H. [8 ]
Navarro, A. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Rambam Med Ctr, Dept Med Oncol, Haifa, Israel
[4] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Med Oncol, Warsaw, Poland
[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[6] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland
[7] Inst Catala Oncol, Barcelona, Spain
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116TiP
引用
收藏
页码：S1425 / S1426
页数：2
相关论文
共 50 条
  • [41] Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
    Goldman, Jonathan W.
    Cummings, Amy Lauren
    Mendenhall, Melody A.
    Velez, Maria A.
    Babu, Sunil
    Johnson, Tirrell T.
    Alcantar, Juan M.
    Dakhil, Shaker R.
    Kanamori, David E.
    Lawler, William E.
    Anand, Sidharth
    Chauv, James
    Garon, Edward B.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Carboplatin and Paclitaxel plus ASA404 as first line chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): A multicenter single arm phase II trial (SAKK 15/08)
    Frueh, M.
    Cathomas, R.
    Siano, M.
    Tscherry, G.
    Zippelius, A.
    Mamot, C.
    Erdmann, A.
    Lohri, A.
    Rauch, D.
    Simcock, M.
    Pless, M.
    ONKOLOGIE, 2011, 34 : 152 - 152
  • [43] SERUM ALBUMIN PREDICTS OUTCOME IN PATIENTS WITH EXTENSIVE STAGE SMALL-CELL LUNG CANCER (ES-SCLC) RECEIVING FIRST-LINE COMBINATION OF PD(L)1 INHIBITORS AND PLATINUM-ETOPOSIDE CHEMOTHERAPY
    Lamberti, Giuseppe
    Ricciuti, Biagio
    Vaz, Victor
    Alessi, Joao Victor
    Pecci, Federica
    Di Federico, Alessandro
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A471 - A471
  • [44] Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
    Zhang, Fan
    Huang, Di
    Li, Tao
    Zhang, Sujie
    Wang, Jinliang
    Zhang, Yuzi
    Wang, Guoqiang
    Zhao, Zhengyi
    Ma, Junxun
    Wang, Lijie
    Sun, Danyang
    Cui, Pengfei
    Cai, Shangli
    Jiao, Shunchang
    Zhao, Lei
    Hu, Yi
    JOURNAL OF CANCER, 2020, 11 (03): : 741 - 749
  • [45] Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study
    Reinmuth, Niels
    Juan-Vidal, Oscar
    Horvath, Zsolt
    Kowalski, Dariusz
    Kryzhanivska, Anna
    Csanky, Eszter
    Galffy, Gabriella
    Bryl, Maciej
    Vicente, David
    Vynnychenko, Ihor
    Papai-Szekely, Zsolt
    Armstrong, Jon
    Dalvi, Tapashi
    Shrestha, Yashaswi
    Xie, Mingchao
    Jiang, Haiyi
    Bondarenko, Igor
    CANCER RESEARCH, 2022, 82 (12)
  • [46] A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
    Cheng, Y.
    Qin, Z.
    Meng, X.
    Xu, F.
    Wang, Y.
    Yao, Y.
    Fang, J.
    Zhao, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1062 - S1062
  • [47] Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
    Krebs, M. G.
    Tarruella, M. Majem
    Forster, M.
    Peguero, J. A.
    Clay, T.
    Felip, E.
    Iams, W.
    Roxburgh, P.
    de Speville, B. Doger
    Bajaj, P.
    Mueller, C.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S33 - S33
  • [48] Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer
    Lu, Jiangyue
    Lei, Xiao
    Zhang, Pei
    Du, Lehui
    Zhang, Zhibo
    Qu, Baolin
    CANCER MEDICINE, 2023, 12 (17): : 17924 - 17933
  • [49] Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
    Cheng, Y.
    Wang, J.
    Yao, W.
    Yu, Y.
    Zang, A.
    Cao, L.
    Lv, D.
    Li, S.
    Meng, Z.
    Zhang, J.
    Guo, Q.
    Huang, D.
    Liu, A.
    Liu, J.
    Mao, W.
    Tang, K.
    Zhang, Y.
    Chen, E.
    Wang, Z.
    Zheng, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1673 - S1673
  • [50] Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
    Facchinetti, Francesco
    Di Maio, Massimo
    Tiseo, Marcello
    CANCERS, 2020, 12 (09) : 1 - 18
12345